Andy Hsieh

Stock Analyst at William Blair

(0.39)
# 4,072
Out of 4,893 analysts
14
Total ratings
28.57%
Success rate
-14.59%
Average return

Stocks Rated by Andy Hsieh

Elevation Oncology
Jun 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.38
Upside: -
Corbus Pharmaceuticals Holdings
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $8.36
Upside: -
Skye Bioscience
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $3.94
Upside: -
Altimmune
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $4.40
Upside: -
Terns Pharmaceuticals
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $4.87
Upside: -
Structure Therapeutics
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $18.90
Upside: -
BioAge Labs
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $4.68
Upside: -
Mersana Therapeutics
Feb 6, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.38
Upside: -
Pyxis Oncology
Nov 21, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.19
Upside: -
Lantheus Holdings
Sep 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $83.83
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $7.35
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $1.55
Upside: -